To participate in this conference call, dial 800-299-0148 (U.S.) or 617-801-9711 (international), passcode: 70506651. The audio webcast can be accessed at: http://www.micromet-inc.com in the investor relations section of the website. A replay of the call will be available from 12:00 pm Eastern Time on November 6, 2008 (6:00 pm Central European Time) through Thursday, November 13, 2008. The replay number is 888-286-8010 (U.S.) or 617-801-6888 (international), passcode: 99269687.
About Micromet, Inc.
Micromet, Inc. (http://www.micromet-inc.com) is a biopharmaceutical company
with offices in Bethesda, MD and Munich, Germany. The Company is focused on
developing novel, proprietary antibodies for the treatment of cancer,
inflammation and autoimmune diseases. The Company's novel antibody
technology is based on its proprietary BiTE antibody platform, representing
a new class of antibodies that specifically activate T cells from the
patient's own immune system to eliminate cancer cells or other disease
related cells. Four of the Company's antibodies are currently in clinical
trials, with the remainder of its product pipeline in preclinical
development. The Company's lead program is a BiTE(R) antibody known as
blinatumomab, or MT103. It is in a phase 2 clinical trial for the treatment
of patients with acute lymphoblastic leukemia and a phase 1 clinical trial
for the treatment of patients with non-Hodgkin's lymphoma. Micromet is
developing blinatumomab in collaboration with MedImmune, Inc., a subsidiary
of AstraZeneca plc. Micromet's second BiTE antibody in clinical development
is MT110, which targets the epithelial cell adhesion molecule (EpCAM). The
Company owns all rights MT 110, which is currently in a phase 1 clinical
trial for the treatment of patients with solid tumors. The Company's third
|SOURCE Micromet, Inc.|
Copyright©2008 PR Newswire.
All rights reserved